You are here: Industry Insights > Market News > AstraZeneca applies for emergency use for vaccine in Philippines

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

SG-DJ10 Capsule and Tablet Sample Checkweigher

NADP+

NMN

Ceritinib (LDK378) CAS:1032900-25-6

SG-JN10 0.1mg Tablet Capsule Check Weigher

β-Nicotinamide Adenine Dinucleotide (NAD+)

AstraZeneca applies for emergency use for vaccine in Philippines

expresspharmaJanuary 07, 2021

Tag: AstraZeneca , COVID-19 vaccine , EUA

Favorites

AstraZeneca has applied to health regulators for emergency use authorisation (EUA) of its COVID-19 vaccine in the Philppines, the food and drugs agency chief said on Wednesday.

AstraZeneca’s application is the second the Philippine Food and Drug Administration (FDA) has received after Pfizer made a similar application last month.

Previous:Indifi partners with Retailio, strengthening its presence in pharma

Next:Australia brings forward COVID-19 vaccine roll-out to early March

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

AstraZeneca applies for emergency use for vaccine in Philippines | Pharmasources.com

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

MetP Pharma AG today announced tirzepatide in a BrainDos™ formulation reduced pro-inflammatory cytokine Il-6 by more than 80% and 2-fold stronger than with aqueous tirzepatide solution.

AstraZeneca applies for emergency use for vaccine in Philippines

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

You may like
More>>

AstraZeneca applies for emergency use for vaccine in Philippines

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

You may likeMore>>

You may like
More>>